Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators
Olga Marchenko,Rajeshwari Sridhara,Qi Jiang,Elizabeth Barksdale,Yuki Ando,Dinesh De Alwis,Katie Brown,Laura Fernandes,Mark T. J. van Bussel,Qiuyi Choo,Michael Coory,Elizabeth Garrett-Mayer,Thomas Gwise,Lorenzo Hess,Rong Liu,Sumithra Mandrekar,Daniele Ouellet,Jose Pinheiro,Martin Posch,Nam Atiqur Rahman,Khadija Rerhou Rantell,Andrew Raven,Sarem,Suman Sen,Mirat Shah,Yuan Li Shen,Richard Simon,Marc Theoret,Ying Yuan,Richard Pazdur
DOI: https://doi.org/10.1080/19466315.2023.2166099
2023-01-01
Statistics in Biopharmaceutical Research
Abstract:The article provides a summary of discussions from the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section Open Forums on March 18th, June 10th, and July 8th of 2022, organized by the ASA BIOP Statistical Methods in Oncology Scientific Working Group in coordination with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence and the LUNGevity Foundation. Diverse stakeholders including oncologists, patient advocates, experts from regulatory agencies across the world, academicians, and representatives from the pharmaceutical industry engaged in a lively discussion on strategies for and designs of dose-optimization studies in cancer drug development. Dose-optimization is one of the major challenges in oncology drug development. The discussions were focused on considerations in designing dose-optimization studies of products for treatment of cancer patients in pre-approval and post-approval stages. Presenters and panelists discussed diverse ideas and methods and agreed that a shift in paradigm is required in oncology drug development that should improve dose optimization while not unnecessarily delaying patient access to potentially efficacious new treatments.